Gediz Dogay Us

Dr. Gediz Dogay Us

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2025 in Hepatology Communications
Verified
Journal Article
Open access
GUGediz Dogay Us
Gediz Dogay Us
FIFrancesco Don Innocenti
Francesco Don Innocenti
OKOzgur Muhammet Koc
Ozgur Muhammet Koc
AEAyşe Eylül
Ayşe Eylül
VYVolkan D. Yumuk
Volkan D. Yumuk
GKGer H. Koek
Ger H. Koek
Background: Dietary interventions are key for managing metabolic dysfunction–associated steatotic liver disease (MASLD), yet optimal diets and the role of PNPLA3 in modulating response to diet remain unclear. We evaluated the efficacy of a Mediterranean diet (MD) versus a low-fat diet (LFD) on hepatic fat and fibrosis, assessing interactions with PNPLA3 genotype. Methods: Two hundred fifty adults with MASLD with BMI ≥25 kg/m 2 were randomized to a 12-week moderately hypocaloric MD or LFD intervention. Individuals with excess alcohol intake and other etiologies of steatosis were excluded. Subjects were genotyped for PNLPA3 single-nucleotide polymorphism. Anthropometric measures, blood tests, and liver assessments [controlled attenuation parameter (CAP) and liver stiffness measurement (LSM)] were conducted at baseline and follow-up. Essential food items were provided, and adherence was tracked using validated questionnaires. The primary outcome was CAP, analyzed using linear mixed models adjusted for age and metabolic syndrome. Results: Both diets significantly reduced CAP, LSM, and body weight at follow-up, with no significant differences between groups. The mean difference between MD and LFD was −0.13 dB/m for CAP ( p =0.976, 95% CI: −8.54, 8.28), −0.19 kPa for LSM ( p =0.355, 95% CI: −0.58, 0.21), and 3.01 kg for weight ( p =0.159, 95% CI: −7.21, 1.19). PNPLA3 genotype did not significantly interact with diet for CAP, LSM, or weight ( p =0.286, p =0.464, p =0.622, respectively). Conclusions: Weight reduction achieved by MD and LFD is similarly efficient in steatosis and fibrosis reduction, while PNPLA3 genotype does not affect the response to diet. Further studies investigating the impact of diet and nutrigenetics on liver-related outcomes are warranted.

11 February 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
GUGediz Dogay Us
Gediz Dogay Us
FIFrancesco Don Innocenti
Francesco Don Innocenti
OKOzgur Muhammet Koc
Ozgur Muhammet Koc
VYVolkan D. Yumuk
Volkan D. Yumuk
ZGZeynep Banu Güngör
Zeynep Banu Güngör
GKGer H. Koek
Ger H. Koek
Background and Aims: Vitamin D plays a pivotal role in liver health, influencing multiple steps in the development of steatosis, fibrosis, and extrahepatic complications in metabolic dysfunction-associated steatotic liver disease (MASLD). However, serum vitamin D concentrations that confer optimal hepatic protection in MASLD remain unclear. We therefore aimed to investigate the association between vitamin D status and MASLD and to explore whether higher vitamin D concentrations confer incremental protection beyond current sufficiency cut-offs. Method: We conducted a multicenter cross-sectional study of 1039 adults with at least one cardiometabolic risk factor for MASLD diagnosis, recruited between 2022 and 2024. Participants that reported excessive alcohol intake (>30 g/day for men, >20 g/day for women) and other etiologies of liver disease were excluded. Serum vitamin D levels were measured, with ≥20 ng/mL defined as sufficiency. MASLD (controlled attenuation parameter [CAP] ≥ 248 dB/m) and significant fibrosis (liver stiffness measurement [LSM] ≥ 8 kPa) were assessed using vibration-controlled transient elastography. Missing vitamin D values were imputed with multiple imputation. Associations between vitamin D status, MASLD and fibrosis were examined using multivariable logistic regression models adjusted for potential confounders. Results: Participants had a mean age of 52.2 ± 13.0 years; 51.6% were male and mean BMI was 30.1 ± 5.8 kg/m2. Vitamin D sufficiency and obesity were present in 81.2% (95% CI: 78.4–84.9) and 54.7% (95% CI: 51.3–58.0), respectively. Vitamin D sufficiency was associated with lower odds of MASLD (crude OR = 0.47, 95% CI: 0.33–0.67) and significant fibrosis (crude OR = 0.46, 95% CI: 0.28–0.76). After adjusting for potential confounders, the association between Vitamin D sufficiency and MASLD remained clinically relevant but did not reach statistical significance (adjusted OR = 0.60, 95% CI: 0.36–1.03, p = 0.06). In contrast, the association between Vitamin D sufficiency and significant fibrosis was both clinically relevant and statistically significant (adjusted OR = 0.48, 95% CI: 0.246–0.916, p = 0.03). When Vitamin D was categorized into quartiles, participants in the highest quartile (≥44 ng/dL) had 61% lower odds of MASLD in the adjusted model (adjusted OR = 0.39, 95% CI: 0.21–0.71) compared with participants in the lowest quartile (≤22 ng/mL). No significant dose-dependent associations were observed for fibrosis. Conclusions: Vitamin D levels showed a dose-dependent decrease in the odds of MASLD among at-risk adults. While the protective effect on fibrosis was not dose-dependent, these findings collectively suggest vitamin D as a potentially modifiable factor in MASLD prevention and management.

1 January 2026 in Hepatology Forum
Verified
Journal Article
Open access
PDF file
Yusuf YilmazYusuf Yilmaz
Yusuf Yilmaz
GAGupse Adali
Gupse Adali
IEIlkay Ergenc
Ilkay Ergenc
EKEda Kaya
Eda Kaya
DGDilara Turan Gokce
Dilara Turan Gokce
RIRamazan Idilman
Ramazan Idilman
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and represents a major and growing public health challenge in Türkiye. This guidance provides an updated, clinically oriented overview of the definition, epidemiology, screening, diagnosis, risk stratification, and management of MASLD, with particular emphasis on evolving nomenclature, non-invasive diagnostic pathways, and current treatment strategies. The document addresses the full clinical spectrum of disease, from steatosis and metabolic dysfunction-associated steatohepatitis (MASH) to advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver transplantation. The guidance also incorporates evidence and practice considerations relevant to the Turkish population, including local epidemiology, resource availability, and implementation challenges in real-world care. Finally, areas of uncertainty and evidence gaps are highlighted to support future research and locally relevant policy development.

12 February 2026 in PLOS ONE
Verified
Journal Article
Open access
GUGediz Dogay Us
Gediz Dogay Us
FIFrancesco Don Innocenti
Francesco Don Innocenti
OKOzgur Muhammet Koc
Ozgur Muhammet Koc
VYVolkan Demirhan Yumuk
Volkan Demirhan Yumuk
ZGZeynep Banu Güngör
Zeynep Banu Güngör
GKGer H. Koek
Ger H. Koek
Background: Turkey represents a high-risk setting for metabolic dysfunction-associated steatotic liver disease (MASLD), with national obesity and diabetes rates of 32% and 15%, respectively. Yet, no prior studies have systematically assessed MASLD and fibrosis prevalence and the independent contribution of these metabolic risk factors in at-risk Turkish populations exhibiting cardiometabolic risks. Methods: 1,039 adults were enrolled in a multicenter cross-sectional study conducted between 2022 and 2024. All participants presented with at least one of the current MASLD diagnostic criteria. Standardized clinical assessments were performed. Individuals with excessive alcohol consumption (<30 grams/day for men and <20 grams/day for women) were excluded. Steatosis and fibrosis were evaluated using controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) via vibration-controlled transient elastography. MASLD was defined as CAP ≥ 248 dB/m, and significant fibrosis as LSM ≥ 8 kPa. Multivariable logistic regression analyses were used to identify factors associated with MASLD and fibrosis. Results: The mean age of the study population was 51.7 ± 13.1 years, and 49.4% were male. The mean body mass index was 30.54 ± 5.85 kg/m 2 . Obesity and central obesity were seen in 48.5% and 75.1% of the subjects, respectively. MASLD, significant fibrosis (>F2) and advanced fibrosis (>F3) prevalence were 57.5% (95% CI: 54.4%–60.4%), 7.6% (95% CI: 6.1%–9.4%) and 2.6% (95% CI: 1.8%–3.8%) respectively. Multivariable logistic regression of MASLD revealed a significant association with female sex (OR=0. 548; 95% CI: 0.391, 0.770), obesity (OR=2.208; 95% CI: 1.535, 3.177), insulin resistance (OR=2.09; 95% CI: 1.528, 2.881), metabolic syndrome (OR=2.436; 95% CI: 1.614, 3.679) and central obesity (OR=2.816; 95% CI: 1.725, 4.595). Multivariable logistic regression of fibrosis demonstrated a significant association with high income (OR=0.256; 95% CI: 0.069, 0.948), obesity (OR=4.845; 95% CI: 2.540, 9.242), diabetes, (OR=2.172; 95% CI: 1.306, 3.610), insulin resistance OR=4.205; 95% CI: 2.144, 8.246) and metabolic syndrome (OR=2.053; 95% CI: 1.042, 4.045). Conclusion: MASLD is prevalent in more than half of the at-risk population studied. Male sex, obesity, metabolic syndrome, insulin resistance and central obesity are significant risk factors associated with it. Despite the high MASLD prevalence, significant fibrosis is less prevalent and is associated with obesity, metabolic syndrome, insulin resistance and diabetes. Further research is warranted in this population. Study Registration: ClinicalTrials.gov, ID: NCT05194553 .

16 September 2026 in Hepatology International
Verified
Journal Article
Open access
PDF file
GUGediz Dogay Us
Gediz Dogay Us
FIFrancesco Innocenti
Francesco Innocenti
OKOzgur Muhammet Koc
Ozgur Muhammet Koc
SESevval İlKe Ebeoglu
Sevval İlKe Ebeoglu
BOBaris Okcun
Baris Okcun
GKGer H. Koek
Ger H. Koek
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) and coronary artery disease (CAD) share common pathophysiologic pathways. However, the relationship between different stages of MASLD and distinct coronary atherosclerosis phenotypes remains unclear. We evaluated the association of hepatic steatosis and fibrosis with coronary artery disease outcomes using paired vibration-controlled transient elastography (VCTE) and coronary computed tomography angiography (CCTA). Methods: 425 adults who underwent both VCTE and CCTA within a three-month interval were included. MASLD was defined as controlled attenuation parameter (CAP) ≥248 dB/m, and significant fibrosis was defined as Liver Stiffness Measurement (LSM) ≥8 kPa. Coronary outcomes were assessed according to Coronary Artery Disease Reporting and Data System guidance. The primary outcome was plaque presence; secondary outcomes included obstructive stenosis, calcified plaque, high segment involvement, and CAD severity. Multivariable logistic regression models were progressively adjusted for demographic, lifestyle, and cardiometabolic factors. Results: MASLD was present in 47.3% of participants. Individuals with MASLD had a higher prevalence of overall plaque than those without (81.6% vs 60.7%, p<0.001), whereas obstructive stenosis did not differ between groups. MASLD was independently associated with higher odds of overall plaque presence after full adjustment (OR 2.22, 95% CI 1.04–4.73; p=0.038). In exploratory analyses, MASLD did not increase the odds of obstructive stenosis, calcified plaque, or CAD severity. In contrast, 1 kPa increase in LSM was associated with higher odds of obstructive stenosis (OR 1.14, 95% CI 1.00–1.30) and calcified plaque (OR 1.18, 95% CI 1.04–1.34), but not CAD presence and severity. Conclusion: MASLD was independently associated with the presence of coronary atherosclerotic plaque. Exploratory analyses further suggested that greater liver stiffness may be associated with obstructive stenosis and calcified plaque, raising the possibility that more advanced liver disease relates to specific features of advanced coronary artery disease. Confirmation in larger prospective studies is warranted.

5 November 2026
Verified
Thesis
Closed access
PDF file
GUGediz Dogay Us
Gediz Dogay Us